Fatty Acid Synthetase Complex (Fatty Acid Synthase)

An enzyme complex of multiple catalytic domains which elongates FATTY ACIDS. The form found in BACTERIA; FUNGI; and PLANTS is different from the form found in ANIMALS. The complex is a target of some ANTINEOPLASTIC AGENTS, some ANTI-OBESITY AGENTS, and some ANTI-INFECTIVE AGENTS.

Also Known As:

Networked: 708 relevant articles (11 outcomes, 57 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Menendez, Javier A: 33 articles (01/2013 - 03/2004)
2.	Lupu, Ruth: 26 articles (01/2013 - 03/2004)
3.	Kuhajda, Francis P: 20 articles (01/2010 - 07/2002)
4.	Loda, Massimo: 18 articles (03/2012 - 08/2003)
5.	Ogino, Shuji: 16 articles (03/2012 - 01/2006)
6.	Colomer, Ramon: 16 articles (01/2011 - 03/2004)
7.	Fuchs, Charles S: 15 articles (03/2012 - 01/2006)
8.	Graner, Edgard: 12 articles (03/2014 - 08/2003)
9.	Nosho, Katsuhiko: 12 articles (04/2011 - 12/2008)
10.	Ronnett, Gabriele V: 12 articles (02/2008 - 07/2002)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2014 - "A large number of studies demonstrate a role of fatty acid synthase in the activation of cell cycle and inhibition of apoptosis in tumor cells. " 07/01/2011 - "This study evaluated and compared, by immunohistochemical reaction, the expression of fatty acid synthase and Ki-67 in salivary gland tumors. " 07/01/2011 - "Few studies have been conducted in oral and salivary gland tumors describing the fatty acid synthase expression. " 07/01/2011 - "Several recent studies have demonstrated a high fatty acid synthase expression in malignant tumors. " 07/01/2011 - "Immunohistochemical study of the expression of fatty acid synthase and Ki-67 in salivary gland tumors."
2.	Carcinoma (Carcinomatosis) 05/01/2014 - "In this study we examined the level of fatty acid synthase expression in surgically resected upper urinary tract urothelial carcinoma specimens and evaluated the relations between fatty acid synthase expression and the patients' pathological features and clinical outcomes. " 07/10/2012 - "This study examined the clinical significance of NAC1 and the expression level of its potential downstream target fatty acid synthase (FASN) in ovarian clear cell carcinomas (OCCCs), and evaluated the NAC1/FASN pathway as a potential therapeutic target. " 01/01/2015 - "Blocking the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of HER2-positive breast carcinoma cells. " 05/01/2014 - "Patients with high fatty acid synthase expression in upper urinary tract urothelial carcinoma should be followed carefully and adjuvant therapy for them should be considered." 05/01/2014 - "Fatty acid synthase expression in upper urinary tract urothelial carcinoma is an independent predictor for tumour recurrence. "
3.	Obesity 01/01/2006 - "Recent studies have shown that FAS (fatty acid synthase) is a potential therapeutic target of obesity. " 11/01/2014 - "Colonic mucosal fatty acid synthase as an early biomarker for colorectal neoplasia: modulation by obesity and gender." 12/18/2013 - "Genome-wide interrogation by BMI suggested differences in gene expression of metabolic and fatty acid genes, including fatty acid synthase (FASN), consistent with the obesity paradox. " 12/01/2013 - "The present work investigated the participation of interscapular brown adipose tissue (IBAT), which is an important site for thermogenesis, in the anti-obesity effects of C75, a synthetic inhibitor of fatty acid synthase (FAS). " 01/01/2013 - "Fatty acid synthase (FAS) is a key enzyme catalyzing the synthesis of fatty acid de novo, and has been considered as an anti-obesity target. "
4.	Fatty Liver 01/01/2013 - "Dietary supplementation with methyl donors reduces fatty liver and modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet." 01/01/2009 - "Serum concentrations of extracellular fatty acid synthase in patients with steatohepatitis." 08/01/2014 - "On the other hand, we observed that expression of miR-130a-3p is decreased in the livers of db/db mice and that adenovirus-mediated overexpression of miR-130a-3p reverses insulin resistance and liver steatosis, the latter of which is achieved via suppressing fatty acid synthase expression in these mice. " 01/01/2015 - "In this study we found that: 1) the expression level of A20 protein was significantly higher in the steatotic liver from MCD-fed mice than the controls; 2) Overexpression of A20 protein suppressed FFAs-stimulated triglyceride deposition in HepG2 cells while under expression of A20 protein increased FFAs-stimulated triglyceride deposition; 3) Overexpression of A20 protein in HepG2 cells upregulated genes that promote β-oxidation and decreased the mRNA levels of key lipogenic genes such as fatty acid synthase (FAS), indicating A20 function as anti-steatotic factor by the activation of mitochondrial β-oxidation and attenuation of de novo lipogenesis; 4) Nonalcoholic steatohepatitis (NASH) patients showed significantly higher A20 expression level in liver compared with control individuals. " 08/05/2014 - "Adenovirus-mediated hepatic overexpression of human 17β-HSD13 induced a fatty liver phenotype in C57BL/6 mice, with a significant increase in mature sterol regulatory element-binding protein 1 and fatty acid synthase levels. "
5.	Hypertriglyceridemia 09/01/2013 - "One was the fatty acid synthase gene, which had an expression constitutively higher in postprandial hypertriglyceridemia rabbits than in Japanese white rabbits during the fasting state and reached quite high levels after feeding. " 12/01/2002 - "This study was performed to test the hypothesis that the increased rate of lipogenesis consequent to upregulation of fatty acid synthase (FAS), a key lipogenic enzyme, gene expression could contribute to overproduction of triacylglycerols and to hypertriglyceridemia in CRF. " 08/01/1998 - "After 3 wk the sucrose-fed rats (compared with the R group) were characterized by the following: 1) higher insulin responses after a glucose challenge (P < 0.05); 2) heavier liver (P < 0.001) and retroperitoneal adipose tissue (P < 0.01); 3) hypertriglyceridemia (P < 0.0001) and higher plasma free fatty acids (P < 0.0001); and 4) higher fatty acid synthase activity in the liver but a low activity in the adipose tissue (P < 0.001). " 04/01/2008 - "Compared with wild-type mice, feeding H-STAT3KO mice with an ethanol-containing diet induced greater hepatic steatosis, hypertriglyceridemia, and hepatic expression of lipogenic genes (sterol regulatory element-binding protein, fatty acid synthase, acetyl-CoA carboxylase-1, and stearoyl-CoA desaturase 1), but less inflammation and lower expression of hepatic proinflammatory cytokines. " 09/27/2013 - "Feeding LA to ZDF rats (a) corrected severe hypertriglyceridemia, (b) lowered abdominal fat mass, (c) raised circulating fibroblast growth factor-21 and Fgf21 liver gene expression, (d) repressed lipogenic gene expression of ATP-citrate synthase (Acly), acetyl-coA carboxylase 1 (Acaca), fatty acid synthase (Fasn), sn-glycerol-3-phosphate acyltransferase 1 (Gpam), adiponutrin (Pnpla3) in the liver and adipose tissue, (e) decreased hepatic protein levels of ACC1/2, FASN and 5'-AMP-activated protein kinase catalytic subunit α (AMPKα), (f) did not change phospho-AMPKα/AMPKα and phospho-ACC/ACC ratios, (g) stimulated liver gene expression of PPARα target genes carnitine O-palmitoyltransferase 1β (Cpt1b) and acyl-CoA thioesterase 1 (Acot1) but not carnitine O-palmitoyltransferase 1α (Cpt1a). "

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Enzymes
3.	Acetyl-CoA Carboxylase
4.	Hexokinase
5.	Sterol Regulatory Element Binding Protein 1
6.	Insulin (Novolin)
7.	Leptin
8.	Biological Markers (Surrogate Marker)
9.	Pyruvate Kinase
10.	Carbon Monoxide

Related Therapies and Procedures

1.	Radiotherapy
2.	Drug Therapy (Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Chemoprevention
5.	Fat-Restricted Diet (Diet, Fat Restricted)